Catalio Capital Management’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19M Sell
497,964
-64,708
-12% -$2.73M 3.52% 9
2026
Q2
$26.5M Sell
562,672
-475,312
-46% -$11.7M 4.97% 6
2026
Q1
$19.6M Buy
+1,037,984
New +$17.6M 4.1% 8

Other funds holding DFTX

Catalio Capital Management's DFTX Position: Q3 2026 in Review

Catalio Capital Management reduced its Definium Therapeutics (DFTX) stake by 12% in Q3 2026, selling an estimated $2.73M and leaving 497,964 shares worth $19M. The position accounts for 3.52% of the portfolio, ranked #9.

Catalio Capital Management first reported a position in DFTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $26.5M in Q2 2026. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Catalio Capital Management held 497,964 shares of Definium Therapeutics worth $19M as of Q3 2026.
  • Catalio Capital Management sold 64,708 Definium Therapeutics shares in Q3 2026, an estimated $2.73M.
  • Definium Therapeutics made up 3.52% of Catalio Capital Management's portfolio in Q3 2026, its #9 holding.
  • Catalio Capital Management first reported a position in Definium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Catalio Capital Management's Definium Therapeutics position peaked at $26.5M in Q2 2026.
  • 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Catalio Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.